Literature DB >> 8971048

Inhibition of viral replication reverses respiratory syncytial virus-induced NF-kappaB activation and interleukin-8 gene expression in A549 cells.

M A Fiedler1, K Wernke-Dollries, J M Stark.   

Abstract

Previous studies have demonstrated that respiratory syncytial virus (RSV) infection of airway epithelial cells results in the expression of a number of cytokines, such as interleukin-8 (IL-8), that are transcriptionally regulated by nuclear factor kappaB (NF-kappaB). In the studies reported here, we demonstrate that treatment of RSV-infected A549 cells with 100 microg of ribavirin (a viral replication inhibitor) per ml results in reversal of RSV-induced NF-kappaB activation, IL-8 mRNA expression, and IL-8 protein production in A549 cells. These data confirm that viral replication is a key step in RSV-induced NF-kappaB activation and IL-8 production.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971048      PMCID: PMC191016     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Induction of interleukin (IL)-8 gene expression by respiratory syncytial virus involves activation of nuclear factor (NF)-kappa B and NF-IL-6.

Authors:  J G Mastronarde; B He; M M Monick; N Mukaida; K Matsushima; G W Hunninghake
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

Review 2.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

3.  Continuing respiratory problems three and a half years after acute viral bronchiolitis.

Authors:  M S Webb; R L Henry; A D Milner; G M Stokes; A S Swarbrick
Journal:  Arch Dis Child       Date:  1985-11       Impact factor: 3.791

4.  Nasal cytokine production in viral acute upper respiratory infection of childhood.

Authors:  T L Noah; F W Henderson; I A Wortman; R B Devlin; J Handy; H S Koren; S Becker
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

5.  Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8.

Authors:  N Mukaida; M Shiroo; K Matsushima
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

6.  Respiratory syncytial virus-induced cytokine production by a human bronchial epithelial cell line.

Authors:  T L Noah; S Becker
Journal:  Am J Physiol       Date:  1993-11

7.  Effect of cytochalasins on surfactant release from alveolar type II cells.

Authors:  W R Rice; K C Osterhoudt; J A Whitsett
Journal:  Biochim Biophys Acta       Date:  1984-09-14

8.  Firefly luciferase gene: structure and expression in mammalian cells.

Authors:  J R de Wet; K V Wood; M DeLuca; D R Helinski; S Subramani
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

9.  Long-term prospective study in children after respiratory syncytial virus infection.

Authors:  C B Hall; W J Hall; C L Gala; F B MaGill; J P Leddy
Journal:  J Pediatr       Date:  1984-09       Impact factor: 4.406

10.  Oxidant tone regulates IL-8 production in epithelium infected with respiratory syncytial virus.

Authors:  J G Mastronarde; M M Monick; G W Hunninghake
Journal:  Am J Respir Cell Mol Biol       Date:  1995-08       Impact factor: 6.914

View more
  25 in total

1.  Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Alexander Kotelkin; Elena A Prikhod'ko; Jeffrey I Cohen; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

2.  Respiratory syncytial virus infection of human alveolar epithelial cells enhances interferon regulatory factor 1 and interleukin-1beta-converting enzyme gene expression but does not cause apoptosis.

Authors:  R Takeuchi; H Tsutsumi; M Osaki; K Haseyama; N Mizue; S Chiba
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 3.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

4.  Respiratory syncytial virus influences NF-kappaB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-kappaB2.

Authors:  Sanjeev Choudhary; Steve Boldogh; Roberto Garofalo; Mohammad Jamaluddin; Allan R Brasier
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Multiple cis regulatory elements control RANTES promoter activity in alveolar epithelial cells infected with respiratory syncytial virus.

Authors:  A Casola; R P Garofalo; H Haeberle; T F Elliott; R Lin; M Jamaluddin; A R Brasier
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  The major component of IkappaBalpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells.

Authors:  M Jamaluddin; A Casola; R P Garofalo; Y Han; T Elliott; P L Ogra; A R Brasier
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

7.  Incomplete regulation of NF-kappaB by IkappaBalpha during respiratory syncytial virus infection in A549 cells.

Authors:  M A Fiedler; K Wernke-Dollries
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 8.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Persistent activation of RelA by respiratory syncytial virus involves protein kinase C, underphosphorylated IkappaBbeta, and sequestration of protein phosphatase 2A by the viral phosphoprotein.

Authors:  V Bitko; S Barik
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Temporal activation of NF-kappaB regulates an interferon-independent innate antiviral response against cytoplasmic RNA viruses.

Authors:  Santanu Bose; Niladri Kar; Ratan Maitra; Joseph A DiDonato; Amiya K Banerjee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.